6-amino-N-(benzyloxy)hexanamide | 515163-50-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-amino-N-(benzyloxy)hexanamide
• 英文别名: 6-amino-N-phenylmethoxyhexanamide
• CAS: 515163-50-5
• 化学式: C₁₃H₂₀N₂O₂
• 分子量: 236.314
• InChiKey: QZXXPIJAYMKWSC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  17
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-amino-N-(benzyloxy)hexanamide 在 N-甲基吗啉 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (7R,8R,11S)-11-(5-Benzyloxycarbamoyl-pentylcarbamoyl)-8-isobutyl-9-oxo-2-oxa-10-aza-bicyclo[11.2.2]heptadeca-1(16),13(17),14-triene-7-carboxylic acid
  参考文献：
  名称：

  Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC)

  摘要：

  A series of succinimide hydroxamic acids was prepared and evaluated in vitro for HDAC inhibition and tumor cell antiproliferation. While the original macrocyclic analogue 6 was quite potent in both assays, several appropriately substituted non-macrocyclic succinimides, such as 23, were equipotent. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00622-4
• 作为产物：
  描述：

  6-溴己酸 在 sodium azide 、 palladium 10% on activated carbon 、 氢气 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 62.0h， 生成 6-amino-N-(benzyloxy)hexanamide
  参考文献：
  名称：

  New Dual CK2/HDAC1 Inhibitors with Nanomolar Inhibitory Activity against Both Enzymes

  摘要：

  Four potent CK2 inhibitors derived from CX-4945 are described. They also provided nanomolar activity against HDAC1, therefore having promising utility as dual-target agents for cancer. The linker length between the hydroxamic acid and the CX-4945 scaffold plays an important role in dictating balanced activity against the targeted enzymes. The seven-carbon linker (compound 15c) was optimal for inhibition of both CK2 and HDAC1. Remarkably, 15c showed 3.0 and 3.5 times higher inhibitory activity than the reference compounds CX-4945 (against CK2) and SAHA (against HDAC1), respectively. Compound 15c exhibited micromolar activity in cell-based cytotoxic assays against multiple cell lines.

  DOI：

  10.1021/acsmedchemlett.9b00561

文献信息

• ISOINDOLINONE DERIVATIVES, PREPARATION METHOD THEREOF AND A PHARMACEUTICAL COMPOSITION COMPRISING SAME
  申请人：Heo Jung Nyoung

  公开号：US20120065396A1

  公开（公告）日：2012-03-15

  The present invention relates to an amide compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition comprising the same. The inventive amide compound facilitates bone formation and inhibits bone loss, and is therefore useful for preventing and treating bone disorders such as osteoporosis, osteodystrophy, bone fracture, periodontal disease, Paget's disease, bone metastasis, and rheumatoid arthritis.

  本发明涉及一种酰胺化合物或其药学上可接受的盐，其制备方法以及包含它的制药组合物。本发明的酰胺化合物促进骨形成并抑制骨丢失，因此可用于预防和治疗骨疾病，如骨质疏松症、骨发育不良、骨折、牙周疾病、Paget病、骨转移和类风湿性关节炎。
• HDAC Inhibitors
  申请人：Ashwell Mark A.

  公开号：US20100261710A1

  公开（公告）日：2010-10-14

  The present invention provides hydroxamic acid compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising the hydroxamic acid compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a compound of the present invention.

  本发明提供了羟肟酸化合物以及这些化合物的制备方法。本发明还涉及包含羟肟酸化合物的药物组合物。本发明提供了治疗细胞增殖性疾病（如癌症）的方法，通过向需要治疗的受试者施用本发明化合物的治疗有效剂量。
• Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same
  申请人：Heo Jung Nyoung

  公开号：US08716326B2

  公开（公告）日：2014-05-06

  The present invention relates to an amide compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition comprising the same. The inventive amide compound facilitates bone formation and inhibits bone loss, and is therefore useful for preventing and treating bone disorders such as osteoporosis, osteodystrophy, bone fracture, periodontal disease, Paget's disease, bone metastasis, and rheumatoid arthritis.

  本发明涉及一种酰胺化合物或其药学上可接受的盐，其制备方法以及包含其的制药组合物。该创新性酰胺化合物促进骨形成并抑制骨丢失，因此可用于预防和治疗骨疾病，如骨质疏松症、骨发育不良、骨折、牙周病、帕吉特病、骨转移和类风湿性关节炎。
• [EN] HDAC INHIBITORS<br/>[FR] INHIBITEURS DES HDAC
  申请人：ARQULE INC

  公开号：WO2009026446A9

  公开（公告）日：2010-03-11
• Indole amide hydroxamic acids as potent inhibitors of histone deacetylases
  作者：Yujia Dai、Yan Guo、Jun Guo、Lori J Pease、Junling Li、Patrick A Marcotte、Keith B Glaser、Paul Tapang、Daniel H Albert、Paul L Richardson、Steven K Davidsen、Michael R Michaelides

  DOI：10.1016/s0960-894x(03)00301-9

  日期：2003.6

  A series of hydroxamic acid-based HDAC inhibitors with an indole amide residue at the terminus have been synthesized and evaluated. Compounds with a 2-indole amide moiety have been found as the most active inhibitors among the different regioisomers. Introduction of substituents on the indole ring further improved the potency and generated a series of very potent inhibitors with significant antiproliferative activity. A representative compound in the series, 7b, has been found to be orally active in tumor growth inhibition model. (C) 2003 Elsevier Science Ltd. All rights reserved.